The Food and Drug Administration has granted Fast Track designation to emrusolmin (TEV-56286) for the treatment of multiple system atrophy.
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback